Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

301. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar)

Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) Diabetes mellitus type 1 and type 2: insulin Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) glargine biosimilar (Abasaglar) Evidence summary Published: 2 December 2015 nice.org.uk/guidance/esnm64 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in December 2015. See summaries of product characteristics (SPCs), British (...) national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary In 2 randomised controlled trials (RCTs) insulin glargine biosimilar (Abasaglar) was as effective as insulin glargine (Lantus) at reducing HbA1c levels in people with type 1 and type 2 diabetes. The safety profile of Abasaglar is comparable to that of Lantus. Regulatory status Regulatory status: Insulin glargine biosimilar 100 units/ml (Abasaglar) received a European marketing

2015 National Institute for Health and Clinical Excellence - Advice

302. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo)

Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) T T ype 1 diabetes mellitus in adults: high-strength ype 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (T insulin glargine 300 units/ml (T oujeo oujeo) ) Evidence summary Published: 13 October 2015 nice.org.uk/guidance/esnm62 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in October 2015. See summaries (...) of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary High-strength insulin products such as insulin glargine 300 units/ml (T oujeo) have been developed for people with large daily insulin requirements to reduce the number and volume of injections. In 1 randomised controlled trial (RCT) in 549 people with type 1 diabetes, T oujeo had similar efficacy to insulin glargine 100 units/ml (Lantus) in terms of HbA1c reduction

2015 National Institute for Health and Clinical Excellence - Advice

303. Type 2 diabetes: insulin degludec/liraglutide (Xultophy)

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) T T ype 2 diabetes: insulin degludec/lir ype 2 diabetes: insulin degludec/liraglutide aglutide (Xultoph (Xultophy) y) Evidence summary Published: 3 July 2015 nice.org.uk/guidance/esnm60 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) - to-date information. Summary In people who are insulin-naïve, insulin degludec/liraglutide (Xultophy) was non-inferior to insulin degludec alone and superior to liraglutide alone for reductions in HbA1c (with a difference of 0.64% compared with liraglutide). In people previously treated with basal insulin, insulin degludec/ liraglutide was superior to insulin degludec alone for reducing HbA1c with a difference of 1.1%. The safety profile and long-term safety concerns of insulin degludec/liraglutide

2015 National Institute for Health and Clinical Excellence - Advice

304. Flowchart: Intrapartum management for gestational diabetes mellitus requiring Insulin and/or Metformin

Flowchart: Intrapartum management for gestational diabetes mellitus requiring Insulin and/or Metformin Document Number: F15.33--2-V1-R20 Department of Health Queensland Clinical Guidelines State of Queensland (Queensland Health) 2015 http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Queensland Clinical Guidelines, Guidelines@health.qld.gov.au Intrapartum management for GDM requiring Insulin and/or Metformin Metformin • Cease when labour established Insulin • Cease when labour (...) established • If morning IOL (and labour not established) o Eat breakfast and give usual rapid acting Insulin o Omit morning long or intermediate acting Insulin • If afternoon IOL (and labour not established) o Give usual mealtime and bedtime Insulin GDM Insulin or Metformin Mode of birth? Day before procedure • Cease Metformin 24 hours prior to procedure • Give usual Insulin the night before procedure Day of morning procedure • Fast from 2400 hours • Omit morning Insulin Monitor BGL 2/24 > 7.0 : greater

2015 Queensland Health

305. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes Full Text available with Trip Pro

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes There are limited data about the effects of sodium-glucose cotransporter 2 inhibitors when used with insulin. We report the efficacy and safety of canagliflozin in patients with type 2 diabetes using insulin.The CANagliflozin CardioVascular Assessment Study is a double-blind, placebo-controlled study that randomized participants (...) to placebo, canagliflozin 100 mg, or canagliflozin 300 mg once daily, added to a range of therapies. The primary end point of this substudy was the change in HbA1c from baseline at 18 weeks among patients using insulin; 52-week effects were also examined.Individuals receiving insulin at baseline were randomized to receive placebo (n = 690), canagliflozin 100 mg (n = 692), or canagliflozin 300 mg (n = 690). These individuals were 66% male and had a median age of 63 years, mean HbA1c of 8.3% (67 mmol/mol

2015 EvidenceUpdates Controlled trial quality: predicted high

306. Effects of high vs low glycemic index of dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: the OmniCarb randomized clinical trial. Full Text available with Trip Pro

Effects of high vs low glycemic index of dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: the OmniCarb randomized clinical trial. Foods that have similar carbohydrate content can differ in the amount they raise blood glucose. The effects of this property, called the glycemic index, on risk factors for cardiovascular disease and diabetes are not well understood.To determine the effect of glycemic index and amount of total dietary carbohydrate on risk factors (...) 135 to 150 participants contributing at least 1 primary outcome measure.(1) A high-glycemic index (65% on the glucose scale), high-carbohydrate diet (58% energy); (2) a low-glycemic index (40%), high-carbohydrate diet; (3) a high-glycemic index, low-carbohydrate diet (40% energy); and (4) a low-glycemic index, low-carbohydrate diet. Each diet was based on a healthful DASH-type diet.The 5 primary outcomes were insulin sensitivity, determined from the areas under the curves of glucose and insulin

2014 JAMA Controlled trial quality: uncertain

307. Insulin degludec (Type 1 diabetes mellitus) ? Benefit assessment according to §35a Social Code Book V

Insulin degludec (Type 1 diabetes mellitus) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Assessment module I, Sections I 2.1 to I 2.6, and Assessment module II, Sections II 2.1 to II 2.6, of the dossier assessment Insulin degludec – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A14-13 Insulin degludec – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-13 Version 1.0 Insulin degludec – Benefit assessment acc. to §35a Social Code Book V 30 July 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec – Benefit assessment according to §35a Social Code Book V

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

308. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. (Abstract)

Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. 25229917 2014 09 30 2015 12 17 1533-4406 371 12 2014 Sep 18 The New England journal of medicine N. Engl. J. Med. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. 1131-41 10.1056/NEJMra1011035 Shulman Gerald I GI From the Howard Hughes Medical Institute and the Departments of Internal Medicine and Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT. eng (...) Humans Hyperglycemia metabolism Insulin Resistance physiology Lipolysis physiology Magnetic Resonance Spectroscopy Mitochondria metabolism Muscle, Skeletal metabolism Obesity metabolism 2014 9 18 6 0 2014 9 18 6 0 2014 10 1 6 0 ppublish 25229917 10.1056/NEJMra1011035

2014 NEJM

309. Antidiabetic activity of 3-hydroxyflavone analogues in high fructose fed insulin resistant rats Full Text available with Trip Pro

Antidiabetic activity of 3-hydroxyflavone analogues in high fructose fed insulin resistant rats Synthetic 3-hydroxyflavone analogues (JY-1, JY-2, JY-3, JY-4), were tested for antidiabetic activity in high-fructose-diet-fed (66 %, for 6 weeks) insulin-resistant Wistar rats (FD-fed rats). The fasting blood glucose, insulin, creatinine and AGEs were decreased to near normal upon treatment with test compounds. Insulin resistance markers such as HOMA-IR, K-ITT, plasma triglycerides, lipids (...) , endogenous antioxidant defense and glycogen were restored in FD-fed rats after treatment with 3-hydroxyflavones. It is known that insulin resistance is partly because of oxidative stress and hence antioxidant activity was determined. They exhibited significant in vitro DPPH and ABTS radical scavenging activity (IC50: 10.66-66.63 µM). Test compounds inhibited ROS and NO production in RAW 264.7 cells (IC50: 10.39-42.63 µM) and they were found as potent as quercetin. Further, the test compounds inhibited

2014 EXCLI journal

310. Levemir penfill (insulin detemir) - Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above

Levemir penfill (insulin detemir) - Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above HAS - Medical, Economic and Public Health Assessment Division 1/33 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 18 December 2013 LEVEMIR PENFILL 100 IU/ml, solution for injection B/5 cartridges of 3 ml (CIP: 34009 365 118-1) LEVEMIR FLEXPEN 100 IU/ml, solution for injection B/5 pre-filled (...) pens of 3 ml (CIP: 34009 365 119-8) LEVEMIR INNOLET 100 IU/ml, solution for injection B/5 pre-filled pens of 3 ml (CIP: 34009 365 120-6) Applicant: NOVO NORDISK PHARMACEUTIQUE SAS INN insulin detemir ATC Code (2013): A10AE05 (Insulins and analogues for injection, long-acting) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indication concerned "Treatment of diabetes mellitus in adults, adolescents and children aged 2 years

2014 Haute Autorite de sante

311. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1) Full Text available with Trip Pro

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1) To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥42 units/day) plus mealtime insulin.EDITION 1 (NCT01499082) was a 6-month, multinational, open-label, parallel-group (...) -treatment differences in tolerability or safety were identified.Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin but with consistently less risk of nocturnal hypoglycemia.© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

2014 EvidenceUpdates Controlled trial quality: predicted high

312. Lantus (insulin glargine) - diabetes mellitus in children aged 2 to 5 years

Lantus (insulin glargine) - diabetes mellitus in children aged 2 to 5 years HAS – Medical, Economic and Public Health Assessment Division 1/12 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2) LANTUS 100 units/ml, solution for injection in cartridge B/5 cartridges of 3 ml (CIP: 34009 354 632 0 3) LANTUS (...) OptiSet 100 units/ml, solution for injection in pre-filled pen B/5 pre-filled pens of 3 ml (CIP: 34009 356 519 7 6) LANTUS SoloStar 100 units/ml, solution for injection in pre-filled pen B/5 pre-filled pens of 3 ml (CIP: 34009 377 229 8 8) Applicant: SANOFI-AVENTIS FRANCE INN insulin glargine ATC code A10AE04 (insulins and analogues for injection, long-acting) Reasons for the review Extension of indication Lists concerned National Health Insurance (French Social Security Code L.162-17) Hospital use

2014 Haute Autorite de sante

313. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial Full Text available with Trip Pro

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial To compare the efficacy and safety of two insulin intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin glargine with metformin and/or pioglitazone.A multinational, randomized, open-label trial that compared insulin lispro low mixture (...) (LM25; n = 236) twice daily with a basal-prandial regimen of insulin glargine once daily and insulin lispro once daily (IGL; n = 240) over 24 weeks in patients with HbA1c 7.5-10.5% and fasting plasma glucose ≤ 6.7 mmol/l. The primary objective was to assess non-inferiority [per-protocol (PP) population], and then superiority [intention-to-treat (ITT) population], of LM25 versus IGL according to change in HbA1c after 24 weeks (non-inferiority margin 0.4%, two-sided significance level 0.05).Estimated

2014 EvidenceUpdates Controlled trial quality: uncertain

314. Inhaled insulin: An Elusive Revolution in Diabetes Management

Inhaled insulin: An Elusive Revolution in Diabetes Management Inhaled insulin: An Elusive Revolution in Diabetes Management. – Clinical Correlations Search Inhaled insulin: An Elusive Revolution in Diabetes Management. June 19, 2014 6 min read By Reed Magleby, MD Peer Reviewed For many with type II diabetes, initiation of insulin therapy represents a devastating progression of their disease. Patients who are dependent on insulin require constant blood sugar monitoring, adherence to strict (...) dosing algorithms, and up to 4 self-administered injections every day. According to a 2010 survey of non-insulin adherent diabetic patients, both “injection phobia” . [1]. In response to these concerns, less invasive administration techniques such as inhaled insulin have been a topic of major interest over the last decade. Accepting inhaled insulin as a replacement for injectable could revolutionize the management of type II diabetes and improve the lives of millions of Americans suffering from

2014 Clinical Correlations

315. Intravenous insulin infusion: the evidence for safe nursing administration practice

Intravenous insulin infusion: the evidence for safe nursing administration practice Intravenous insulin infusion: the evidence for safe nursing administration practice Intravenous insulin infusion: the evidence for safe nursing administration practice Lavenberg JG, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lavenberg JG, Umscheid CA. Intravenous (...) insulin infusion: the evidence for safe nursing administration practice. Philadelphia: Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Infusions, Intravenous; Insulin; Nursing Care Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St

2014 Health Technology Assessment (HTA) Database.

316. Glucose monitoring and insulin administration for patients receiving total enteral nutrition

Glucose monitoring and insulin administration for patients receiving total enteral nutrition Glucose monitoring and insulin administration for patients receiving total enteral nutrition Glucose monitoring and insulin administration for patients receiving total enteral nutrition Lavenberg JG, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lavenberg (...) JG, Umscheid CA. Glucose monitoring and insulin administration for patients receiving total enteral nutrition. Philadelphia: Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Blood Glucose; Enteral Nutrition; Humans; Insulin Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University

2014 Health Technology Assessment (HTA) Database.

317. Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial Full Text available with Trip Pro

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. This trial compared IDegAsp with biphasic insulin aspart 30 (BIAsp 30) in adults with type 2 diabetes inadequately controlled with once- or twice-daily (...) (OD or BID) pre- or self-mixed insulin with or without oral antidiabetic drugs.In this 26-week, randomized, open-label, multinational, treat-to-target trial, participants (mean age 58.7 years, duration of diabetes 13 years, BMI 29.3 kg/m(2), and HbA1c 8.4% [68 mmol/mol]) were exposed (1:1) to BID injections of IDegAsp (n = 224) or BIAsp 30 (n = 222), administered with breakfast and the main evening meal and dose titrated to a self-measured premeal plasma glucose (PG) target of 4.0-5.0 mmol/L.After

2014 EvidenceUpdates Controlled trial quality: uncertain

318. Insulin use: numerous preventable errors

Insulin use: numerous preventable errors Prescrire IN ENGLISH - Spotlight ''Insulin use: numerous preventable errors'', 1 January 2014 {1} {1} {1} | | > > > Insulin use: numerous preventable errors Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Insulin use: numerous preventable errors Insulin-related errors are frequent and often preventable (...) . It is better for health professionals to listen to patients, who are often adept at managing their treatment. Insulin is vital for patients with type 1 diabetes and useful for some type 2 diabetics. Its use is delicate since the dosage needs to be tailored to each patient, and the consequences of dosage errors can be severe: hypoglycaemia with convulsions, coma, even death in the case of overdose; hyperglycaemia, sometimes fatal ketoacidosis in the case of insufficient dosage. Training in the use

2014 Prescrire

319. Effects of different intensities of physical exercise on insulin sensitivity and protein kinase B/Akt activity in skeletal muscle of obese mice. (Abstract)

Effects of different intensities of physical exercise on insulin sensitivity and protein kinase B/Akt activity in skeletal muscle of obese mice. To investigate the effects of different intensities of acute exercise on insulin sensitivity and protein kinase B/Akt activity in skeletal muscle of obese mice.Swiss mice were randomly divided into four groups, and fed either a standard diet (control group) or high fat diet (obese sedentary group and obese exercise group 1 and 2) for 12 weeks. Two (...) different exercise protocols were used: swimming for 1 hour with or without an overload of 5% body weight. The insulin tolerance test was performed to estimate whole-body sensitivity. Western blot technique was used to determine protein levels of protein kinase B/Akt and phosphorylation by protein Kinase B/Akt in mice skeletal muscle.A single bout of exercise inhibited the high fat diet-induced insulin resistance. There was increase in phosphorylation by protein kinase B/Akt serine, improve in insulin

2014 Einstein (Sao Paulo, Brazil)

320. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia Full Text available with Trip Pro

The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia OBJECTIVE Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS (...) The ORIGIN trial is an international, long-term, randomized two-by-two factorial study comparing insulin glargine with standard care and n-3 fatty acids with placebo (double blind) in people with dysglycemia at high risk for cardiovascular events. The primary outcome measure (cancer substudy) was the occurrence of any new or recurrent adjudicated cancer. Cancer mortality and cancer subtypes were also analyzed. RESULTS Among 12,537 people (mean age 63.5 years, SD 7.8; 4,388 females), 953 developed

2014 EvidenceUpdates Controlled trial quality: predicted high